ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Sunday, November 13, 2016

4:30PM-6:00PM
Abstract Number: 1055
Physical Activity Behavior in Men with Inflammatory Arthritis: A Cross-Sectional Register Based Study of Physical Activity Correlates, Motivators, Barriers and Preferences
ARHP II: Healthcare Disparities and and Psychosocial Impact on Rheumatic Disease
4:30PM-6:00PM
Abstract Number: 1009
Plasmacytoid Dendritic Cells Are Activated in Systemic Sclerosis and Contribute to the Disease By Inducing Ifnα and CXCL4
Innate Immunity and Rheumatic Disease
4:30PM-6:00PM
Abstract Number: 1002
Pneumocystis Jiroveci in Rheumatic Disease: A 20 Year Single-Center Experience
Infection-related Rheumatic Disease
4:30PM-6:00PM
Abstract Number: 1015
Pro-Inflammatory Cytokines Produced By Different Subsets of Peripheral Blood Mononuclear Cells Are Associated with Ro52/TRIM21 Deficiency in Patients with Inflammatory Myopathies
Muscle Biology, Myositis and Myopathies
4:30PM-6:00PM
Abstract Number: 1020
Risk Factors Can Classify Individuals Who Develop Accelerated Knee Osteoarthritis
Osteoarthritis – Clinical Aspects I: Epidemiology and Progression
4:30PM-6:00PM
Abstract Number: 988
Risk of Rheumatoid Arthritis after Transfusion of Blood from Donors Later Diagnosed with  Rheumatoid Arthritis: A Retrospective Cohort Study
Epidemiology and Public Health I: Inflammatory Arthritis – Risk and Impact
4:30PM-6:00PM
Abstract Number: 1043
Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through Week 28
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II: Axial Spondyloarthritis – Treatment
4:30PM-6:00PM
Abstract Number: 1054
Self-Reported Psychological Impact and Coping Strategies of Men with RA
ARHP II: Healthcare Disparities and and Psychosocial Impact on Rheumatic Disease
4:30PM-6:00PM
Abstract Number: 1016
Soluble BAT-3: A New Biomarker for Antisynthetase Syndrome
Muscle Biology, Myositis and Myopathies
4:30PM-6:00PM
Abstract Number: 1017
Statistical Simulation Using Data from the Foundation for the National Institute of Health/Osteoarthritis Initiative Biomarkers Consortium to Evaluate the Clinical Utility of Prognostic Knee Osteoarthritis Biomarkers in Designing a Knee Osteoarthritis Clinical Trial
Osteoarthritis – Clinical Aspects I: Epidemiology and Progression
4:30PM-6:00PM
Abstract Number: 1040
Stressful Life Events : A Trigger for Rheumatoid Arthritis Onset within a Year. a Case-Control Study
Rheumatoid Arthritis – Clinical Aspects I: Pre-RA and Progression to Rheumatoid Arthritis
4:30PM-6:00PM
Abstract Number: 1000
Subclinical Cytomegalovirus Viremia Is Associated with Increased Nosocomial Infections and Prolonged Hospitalization in Patients with Systemic Autoimmune Diseases
Infection-related Rheumatic Disease
4:30PM-6:00PM
Abstract Number: 1024
Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis
4:30PM-6:00PM
Abstract Number: 1030
Synovial Tissue Resident Macrophages Play the Protective Role in the Development of Inflammatory Arthritis in CD11c-Flip-KO Mice
Rheumatoid Arthritis – Animal Models I
4:30PM-6:00PM
Abstract Number: 1033
Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis
Rheumatoid Arthritis – Animal Models I
  • «Previous Page
  • 1
  • …
  • 67
  • 68
  • 69
  • 70
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology